COVID-19 explained

COVID-19 is a highly contagious disease caused by a strain of coronavirus, SARS-CoV2. While around two per cent of people who get the flu in a typical season have severe or life-threatening complications requiring hospitalisation, around 10 per cent of COVID-19 cases result in life-threatening complications.

COVID-19 is set to be the third-leading cause of death in Australia in the first seven months of 2022, after ischaemic heart disease and dementia, and ahead of cerebrovascular disease and lung cancer.

What is coronavirus?

How did COVID-19 get its name?

How is COVID-19 spread?

Coronavirus symptoms, diagnosis and treatment

Our COVID-19 research

COVID-19 has highlighted how damaging out-of-control inflammation can be. Patients with severe COVID-19 develop out-of-control inflammation as their bodies try to fight the virus. This triggers a severe hyper-inflammatory response leading to acute respiratory distress syndrome (ARDS) and organ failure. Restricting this inflammatory response could help save lives.

Hudson Institute researchers are using their world-leading inflammation expertise to understand how this response happens and develop treatments to mitigate the deadly inflammation caused by COVID-19.

“There is still so much we don’t know about the dangerous and damaging inflammation that leads to acute respiratory distress syndrome, chronic obstructive pulmonary disease, cancer, heart disease, kidney disease, inflammatory bowel disease and more,” Prof Hartland says.

“Hudson Institute already has 150 expert scientists and clinicians working on inflammation – the largest concentration of inflammation researchers in Australia.”

Professor Elizabeth Hartland, CEO, discusses inflammation. LISTEN TO PODCAST HERE

Cancer drug investigated for severe COVID-19 treatment

Dr Michael Gantier from the Nucleic Acids and Innate Immunity Research Group at Hudson InstituteThe team discovered that an existing cancer drug could help limit toxic inflammation arising with low oxygen levels in severe COVID-19 patients.  Industry partner, Noxopharm, is conducting a Phase I clinical trial in severe COVID-19 patients in Eastern Europe to determine the therapeutic potential of this approach to decrease COVID-19 mortality. This work has seen a new Australian drug development company formed as the result of a collaboration between Noxopharm Limited (ASX:NOX) and Hudson Institute, with a specific focus on life-threatening inflammation.

Lead Researcher | Associate Professor Michael Gantier

Single gene disorder in the innate immune pathway in infectious and inflammatory disease

Using your immune system to fight COVID-19


COVID-19 collaborators

Support for people with COVID-19

Hudson Institute scientists cannot provide medical advice.
Find out more about COVID-19.

Share this page